DRG 329 Overview

DRG 329 covers major small and large bowel surgical procedures when a Major Complication or Comorbidity is present, typically including extensive resections, anastomoses, or procedures for perforation, ischemia, obstruction, or severe inflammatory disease with significant physiologic instability. This Diagnosis-Related Group groups higher-resource cases with critical intraoperative or postoperative complexity, which increases allowable Medicare inpatient reimbursement relative to less complex bowel procedure groups. Accurate capture of principal procedure codes and documented Major Complication or Comorbidity drives appropriate payment assignment. The grouping reflects expected higher resource use, longer inpatient stays, and greater clinical intensity.

Across commercial payers the negotiated rate range for DRG 329 spans from $40K (BCBS min) up to $170K (Anthem max), with payer medians clustered between $42K and $80K. The widest spread between payer minimums and maximums is seen with Anthem versus BCBS at roughly $130K. See the table and chart below for payer-specific quartiles and distribution details.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 329. These figures reflect Medicare FFS payment experience at the national level for 2023.

• Acute perioperative intervention trials focusing on strategies to reduce surgical morbidity and mortality in patients undergoing major small and large bowel resections for emergent or complicated disease (for example ischemic bowel, perforation, or obstructive malignancy). These studies enroll high-acuity inpatients typically with sepsis risk, hemodynamic instability, or contamination of the peritoneal cavity and test interventions such as optimized fluid resuscitation protocols, timing of source control, intraoperative techniques to reduce anastomotic leak, or standardized sepsis bundles. Findings are directly relevant to surgeons, intensivists, and hospital payers because improvements can reduce ICU days, reoperation rates, complication-related coding changes (MCC attribution), and overall inpatient costs.
• Comparative effectiveness trials evaluating surgical approaches and perioperative care pathways for elective or semi-elective major bowel procedures in patients with underlying malignancy, inflammatory bowel disease, or complex diverticular disease. These studies compare open versus minimally invasive techniques, primary anastomosis versus staged procedures with diversion, or enhanced recovery after surgery (ERAS) protocols, and typically enroll patients who are stable enough for definitive operations but have high comorbidity burdens. Results inform decisions about procedure selection and care standardization that affect length of stay, readmission risk, and resource utilization—key concerns for clinicians and payers seeking to optimize outcomes while controlling reimbursement-driven metrics.
• Post-discharge and outcomes research focusing on long-term functional recovery, stoma reversal timing, and health-care utilization among survivors of major small and large bowel surgery who incurred major complications during the index admission. These cohort or pragmatic studies follow patients after discharge to measure readmissions, persistent organ dysfunction, return to baseline nutrition and mobility, and durable quality-of-life outcomes, often stratified by presence of MCC during the hospitalization. Providers and payers rely on this evidence to design transitional care programs, determine follow-up intensity, and predict downstream costs associated with chronic care needs or late complications stemming from the index DRG episode.